TREM2 and neoplasm: OPA, a platinum (IV)-based compound derived from Oxaliplatin (OP) and Artesunate (ART), has been shown to diminish TREM2 expression in macrophages, facilitating their polarization from an immunosuppressive M2 phenotype to an anti-tumor M1 phenotype.